About Us

Auransa Announce Research Collaboration with POLARISqb

Artificial Intelligence, AI, Machine Learning, ML, Natural Language Processing (NLP), Deep Learning, DL, AI Model, AI-powered Solutions, Digital Transformation, ML Model, Natural Language Understanding, NLU, AI News, Artificial Intelligence News
A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Auransa, Inc., an AI-driven pharmaceutical startup company that aims at developing precise medicines for cancer, aging-related diseases, and other disorders, recently announced a collaboration with POLARISqb (Polaris Quantum Biotech). This partnership will point out available treatments for women’s neglected diseases.

Pek Lum, Ph.D., CEO of Auransa, shared his thoughts, “We are excited about collaborating with Polaris to undertake a neglected area in the pharmaceutical industry. As women CEOs, we have joined forces to tackle female diseases like endometriosis, polycystic ovary syndrome, triple-negative breast cancer, or ovarian cancer. Together, I believe that we will be able to combine our expertise in biology and chemistry to generate quality solutions for hard to tackle or neglected diseases affecting women’s health.”

This collaboration will address the discovery of various treatments for diseases and proper medical research for their solution. In this partnership, POLARISqb will merge its POLARISqb’s TachyonTM platform, which articulates billions of molecules from a huge area to find novel molecular drugs with Auransa’s proprietary predictive computational platform, SMarTR™ Engine, to tackle neglected diseases of women.

POLARISqb, the first drug discovery platform built which utilizes Quantum Computing, Artificial Intelligence, Machine Learning, and Personalized Medicine to Revolutionize Drug Design. According to the CEO of POLARISqb, Dr. Shahar Keinan, “Quantum Computing technology is coming of age, allowing us to shorten the time to discover new drugs and scale up to multiple targets.”

He further added, “We are thrilled to be able to combine our technology with Auransa’s and tackle neglected diseases affecting women. Together, we have unique perspectives on the industry and of unmet needs the pharmaceutical industry can and should tackle, utilizing the best technology available.”

Recent News